Spring til hovednavigation
Spring til søgning
Spring til hovedindhold
Sorter
Keyphrases
Prognostic Value
100%
Copd
100%
Clinically Important Deterioration
100%
Trial Sequential Analysis
100%
Deterioration Risk
27%
Dual Therapy
27%
Fluticasone Furoate/umeclidinium/vilanterol
27%
Clinical Outcomes
18%
Health Status
18%
Chronic Obstructive Pulmonary Disease
18%
Severe Exacerbation
18%
Disease Worsening
18%
Multicenter Trial
9%
All-cause Mortality
9%
Long-term Prognosis
9%
Forced Expiratory Volume in 1 Second (FEV1)
9%
Long-term Clinical Outcome
9%
St. George's Respiratory Questionnaire
9%
Exacerbation Rate
9%
IMPACT Trial
9%
Lung Health
9%
Prognostic Analysis
9%
Single Inhaler
9%
Chronic Obstructive Pulmonary Disease Assessment Test
9%
Lung Function Status
9%
Nursing and Health Professions
Deterioration
100%
Clinical Outcome
25%
Obstructive Lung Disease
25%
Fluticasone Furoate Plus Umeclidinium Plus Vilanterol
25%
Health Status
16%
Diseases
16%
All Cause Mortality
8%
Forced Expiratory Volume
8%
Disease Assessment
8%
St. George Respiratory Questionnaire
8%
Inhaler
8%
Medicine and Dentistry
Deterioration
100%
Chronic Obstructive Pulmonary Disease
25%
Fluticasone Furoate Plus Umeclidinium Plus Vilanterol
25%
Health Status
16%
Diseases
16%
All Cause Mortality
8%
Forced Expiratory Volume
8%
Disease Assessment
8%
St. George Respiratory Questionnaire
8%
Lung
8%
Pharmacology, Toxicology and Pharmaceutical Science
Deterioration
100%
Chronic Obstructive Lung Disease
25%
Fluticasone Furoate Plus Umeclidinium Plus Vilanterol
25%
Health Status
16%
Diseases
16%
All Cause Mortality
8%